Novartis ophthalmology clinical trials. This is a phase 2, multi-part, five-year, randomized, open-label, assessor-blinded, multicenter study to evaluate the efficacy and safety of Jan 31, 2025 · • Novartis announces Phase 3 data for pelacarsen, an Lp(a)-lowering antisense therapy, is now expected in first half of 2026, with regulatory submissions planned for second half. On the . They are exploring innovative treatments beyond current Frederic Guerard, Novartis’ franchise head of ophthalmology, provides insight into his team’s strategy for brolucizumab while keeping its global commitment to Lucentis, along with plans for gene therapy and digital technology. 4 days ago · Novartis has signed a multi-year agreement with RetinAI, which will see the companies work together to use artificial intelligence (AI) tools to support ophthalmology and digital health projects Apr 26, 2018 · A new smartphone app lets patients participate in ophthalmology trials without stepping foot in a clinic. October 2023: Novartis AG launched a new sustained-release therapy for age-related macular degeneration. Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Novartis is aware of employment scams which make false use of our company name or leader’s names to defraud job seekers. Notice to applicants for US job openings. Jul 5, 2018 · Novartis introduces the FocalView app, enabling patients to participate in ophthalmology clinical trials from home. 1 day ago · Clostridium Difficile Infections Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Novartis AG, Astellas Pharma, Eli Lilly, AstraZeneca Sep 11, 2023 · As Novartis looks to sell off its eye disease unit, a geographic atrophy program from a 2021 acquisition is being discontinued on weak data. Jan 19, 2025 · Novartis is advancing its research in ophthalmology to address the growing issue of vision loss, which affects approximately 253 million people globally. 6 days ago · A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead. Learn more about clinical trials at Novartis, including opportunities to get involved. There was activity in gene therapy for ocular diseases at all levels Jan 21, 2026 · Recruiting Clinical Trials A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) Feb 20, 2026 · The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab. Learn More Be aware of fake job advertisements and job offers. Feb 28, 2026 · In this review period, the US Food and Drug Administration (FDA) approved a combination drug/device product for the treatment of keratoconus, and another biosimilar aflibercept gained regulatory approval. Cantonal Hosptial Aarau, Department of Ophthalmology, Aarau, Switzerland Completed Reproducibility of Blood Flowmetry in Human Retina Using the Nidek Laser Speckle Flowgraphy LSFG-NAVI System (LSFG Repro) Healthy | Open Angle Glaucoma | Normal Tension Glaucoma Switzerland University Hospital, Basel, Switzerland Cantonal Hospital of Aarau Novartis Pharmaceuticals Active, not recruiting A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) (ASTRALS) Amyotrophic Lateral Sclerosis (ALS) 3 days ago · Prospects for Novartis' ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD). Learn how this innovative platform could revolutionize clinical trial participation and enhance patient engagement in eye care research. 5 days ago · November 2023: Aerie Pharmaceuticals announced positive top-line results from a Phase 3 clinical trial for a novel glaucoma treatment. • The Lp(a)HORIZON trial, involving over 8,000 patients, aims to be the first cardiovascular outcomes study evaluating Lp(a) reduction's impact on cardiovascular risk. Novartis does not make job offers without interview and never asks candidates for money. • Developed by Ionis and licensed to Dec 30, 2025 · This non-interventional observational, prospective cohort study is using primary data collection to describe the routine clinical practice and HRQoL of patients with Metastatic castration-resistant prostate cancer (mCRPC) initiating lutetium (177Lu) vipivotide tetraxetan using patient questionnaires. Career Search Explore opportunities with Novartis below. Led by Cynthia Grosskreutz, the team is focused on unmet medical needs, particularly in conditions like age-related macular degeneration (AMD), glaucoma, and ocular surface diseases. Novartis’ FocalView app guides patients through self-assessments of visual function and disease activity, streaming large volumes of real-world data directly into researchers’ hands. All our current job I’m pleased to share that our recent work, the first cost-effectiveness study comparing #faricimab and #aflibercept for the treatment of neovascular age-related macular degeneration (#nAMD) in Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting. Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information. The results of phase 3 clinical trials were announced for treatments for uveitic macular edema and Sjögren’s disease. Stay updated on the latest advancements in digital health and ophthalmology. vjhxiphu epe kgit tpijv vmdvoov ane xhispxe arqd edlqc zushi